MiNK Therapeutics Inc (INKT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$11.64+3.65%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · INKT
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | |||||||
| R&D Expenses | 5.7 | 5.8 | 6.3 | 15.5 | 23.1 | 14.0 | 9.5 |
| Operating Income | (12.0) | (12.6) | (11.3) | (22.9) | (30.9) | (28.4) | (14.6) |
| Earnings from Continuing Operations | |||||||
| Interest Expense | (0.1) | (0.1) | (0.1) | (0.0) | — | 2.4 | 2.4 |
| Net Income | |||||||
| Net Income | (11.4) | (12.5) | (10.8) | (22.5) | (28.0) | (30.2) | (16.2) |
| Per Share | |||||||
| Basic EPS | (2.26) | (2.93) | (2.86) | (6.54) | (0.83) | (1.16) | — |
| Diluted EPS | (2.26) | (2.93) | (2.86) | (6.54) | (0.83) | (1.16) | — |
| Basic Weighted Avg Shares | 5.0 | 4.3 | 3.8 | 3.4 | 33.7 | 26.0 | — |
| Diluted Weighted Avg Shares | 5.0 | 4.3 | 3.8 | 3.4 | 33.7 | 26.0 | — |
| Supplemental | |||||||
| EBIT | (12.0) | (12.6) | (11.3) | (22.9) | (30.9) | (28.4) | (14.6) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.